Levels of symptom burden during chemotherapy for advanced lung cancer: Differences between public hospitals and a tertiary cancer center

Charles S. Cleeland, Tito R. Mendoza, Xin Shelley Wang, Jeanie F. Woodruff, Guadalupe R. Palos, Stephen P Richman, Arlene Nazario, Garrett R. Lynch, Kai Ping Liao, Gary M. Mobley, Charles Lu

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: We compared risk factors for high disease- and treatment-related symptom burden over 15 weeks of therapy in medically underserved patients with advanced non - small-cell lung cancer and in patients treated at a tertiary cancer center. Patients and Methods: We monitored symptom severity weekly during chemotherapy. Patients were recruited from a tertiary cancer center (n = 101) and three public hospitals treating the medically underserved (n = 80). We used a composite symptom-severity score and group-based trajectory analysis to form two groups: one with consistently more severe symptoms and another with less severe symptoms. We examined predictors of group membership. Results: Seventy percent of the sample (n = 126) reported low symptom-severity levels that decreased during therapy; 30% (n = 55) had consistently severe symptoms throughout the study. In multivariate analysis, patients with good performance status being treated in public hospitals were significantly more likely than patients treated at the tertiary cancer center to be in the highsymptom group (odds ratio, 5.6; 95% CI, 2.1 to 14.6; P = .001) and to report significantly higher symptom interference (P = .001). Other univariate predictors of high-symptom group membership included variables associated with being medically underserved (eg, having less education, being single, and being nonwhite). No group differences by ethnicity were observed in the public hospitals. Medically underserved patients were less likely to receive adequate pain management. Conclusion: Patients with advanced lung cancer and good performance status treated at public hospitals were more likely than those treated at a tertiary cancer center to experience substantial symptoms during chemotherapy.

Original languageEnglish
Pages (from-to)2859-2865
Number of pages7
JournalJournal of Clinical Oncology
Volume29
Issue number21
DOIs
StatePublished - Jul 20 2011

Fingerprint

Public Hospitals
Lung Neoplasms
Drug Therapy
Neoplasms
Vulnerable Populations
Pain Management
Non-Small Cell Lung Carcinoma
Therapeutics
Multivariate Analysis
Odds Ratio
Education

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Levels of symptom burden during chemotherapy for advanced lung cancer : Differences between public hospitals and a tertiary cancer center. / Cleeland, Charles S.; Mendoza, Tito R.; Wang, Xin Shelley; Woodruff, Jeanie F.; Palos, Guadalupe R.; Richman, Stephen P; Nazario, Arlene; Lynch, Garrett R.; Liao, Kai Ping; Mobley, Gary M.; Lu, Charles.

In: Journal of Clinical Oncology, Vol. 29, No. 21, 20.07.2011, p. 2859-2865.

Research output: Contribution to journalArticle

Cleeland, CS, Mendoza, TR, Wang, XS, Woodruff, JF, Palos, GR, Richman, SP, Nazario, A, Lynch, GR, Liao, KP, Mobley, GM & Lu, C 2011, 'Levels of symptom burden during chemotherapy for advanced lung cancer: Differences between public hospitals and a tertiary cancer center', Journal of Clinical Oncology, vol. 29, no. 21, pp. 2859-2865. https://doi.org/10.1200/JCO.2010.33.4425
Cleeland, Charles S. ; Mendoza, Tito R. ; Wang, Xin Shelley ; Woodruff, Jeanie F. ; Palos, Guadalupe R. ; Richman, Stephen P ; Nazario, Arlene ; Lynch, Garrett R. ; Liao, Kai Ping ; Mobley, Gary M. ; Lu, Charles. / Levels of symptom burden during chemotherapy for advanced lung cancer : Differences between public hospitals and a tertiary cancer center. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 21. pp. 2859-2865.
@article{1c883675572d4f328309cf7ff2e2c350,
title = "Levels of symptom burden during chemotherapy for advanced lung cancer: Differences between public hospitals and a tertiary cancer center",
abstract = "Purpose: We compared risk factors for high disease- and treatment-related symptom burden over 15 weeks of therapy in medically underserved patients with advanced non - small-cell lung cancer and in patients treated at a tertiary cancer center. Patients and Methods: We monitored symptom severity weekly during chemotherapy. Patients were recruited from a tertiary cancer center (n = 101) and three public hospitals treating the medically underserved (n = 80). We used a composite symptom-severity score and group-based trajectory analysis to form two groups: one with consistently more severe symptoms and another with less severe symptoms. We examined predictors of group membership. Results: Seventy percent of the sample (n = 126) reported low symptom-severity levels that decreased during therapy; 30{\%} (n = 55) had consistently severe symptoms throughout the study. In multivariate analysis, patients with good performance status being treated in public hospitals were significantly more likely than patients treated at the tertiary cancer center to be in the highsymptom group (odds ratio, 5.6; 95{\%} CI, 2.1 to 14.6; P = .001) and to report significantly higher symptom interference (P = .001). Other univariate predictors of high-symptom group membership included variables associated with being medically underserved (eg, having less education, being single, and being nonwhite). No group differences by ethnicity were observed in the public hospitals. Medically underserved patients were less likely to receive adequate pain management. Conclusion: Patients with advanced lung cancer and good performance status treated at public hospitals were more likely than those treated at a tertiary cancer center to experience substantial symptoms during chemotherapy.",
author = "Cleeland, {Charles S.} and Mendoza, {Tito R.} and Wang, {Xin Shelley} and Woodruff, {Jeanie F.} and Palos, {Guadalupe R.} and Richman, {Stephen P} and Arlene Nazario and Lynch, {Garrett R.} and Liao, {Kai Ping} and Mobley, {Gary M.} and Charles Lu",
year = "2011",
month = "7",
day = "20",
doi = "10.1200/JCO.2010.33.4425",
language = "English",
volume = "29",
pages = "2859--2865",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "21",

}

TY - JOUR

T1 - Levels of symptom burden during chemotherapy for advanced lung cancer

T2 - Differences between public hospitals and a tertiary cancer center

AU - Cleeland, Charles S.

AU - Mendoza, Tito R.

AU - Wang, Xin Shelley

AU - Woodruff, Jeanie F.

AU - Palos, Guadalupe R.

AU - Richman, Stephen P

AU - Nazario, Arlene

AU - Lynch, Garrett R.

AU - Liao, Kai Ping

AU - Mobley, Gary M.

AU - Lu, Charles

PY - 2011/7/20

Y1 - 2011/7/20

N2 - Purpose: We compared risk factors for high disease- and treatment-related symptom burden over 15 weeks of therapy in medically underserved patients with advanced non - small-cell lung cancer and in patients treated at a tertiary cancer center. Patients and Methods: We monitored symptom severity weekly during chemotherapy. Patients were recruited from a tertiary cancer center (n = 101) and three public hospitals treating the medically underserved (n = 80). We used a composite symptom-severity score and group-based trajectory analysis to form two groups: one with consistently more severe symptoms and another with less severe symptoms. We examined predictors of group membership. Results: Seventy percent of the sample (n = 126) reported low symptom-severity levels that decreased during therapy; 30% (n = 55) had consistently severe symptoms throughout the study. In multivariate analysis, patients with good performance status being treated in public hospitals were significantly more likely than patients treated at the tertiary cancer center to be in the highsymptom group (odds ratio, 5.6; 95% CI, 2.1 to 14.6; P = .001) and to report significantly higher symptom interference (P = .001). Other univariate predictors of high-symptom group membership included variables associated with being medically underserved (eg, having less education, being single, and being nonwhite). No group differences by ethnicity were observed in the public hospitals. Medically underserved patients were less likely to receive adequate pain management. Conclusion: Patients with advanced lung cancer and good performance status treated at public hospitals were more likely than those treated at a tertiary cancer center to experience substantial symptoms during chemotherapy.

AB - Purpose: We compared risk factors for high disease- and treatment-related symptom burden over 15 weeks of therapy in medically underserved patients with advanced non - small-cell lung cancer and in patients treated at a tertiary cancer center. Patients and Methods: We monitored symptom severity weekly during chemotherapy. Patients were recruited from a tertiary cancer center (n = 101) and three public hospitals treating the medically underserved (n = 80). We used a composite symptom-severity score and group-based trajectory analysis to form two groups: one with consistently more severe symptoms and another with less severe symptoms. We examined predictors of group membership. Results: Seventy percent of the sample (n = 126) reported low symptom-severity levels that decreased during therapy; 30% (n = 55) had consistently severe symptoms throughout the study. In multivariate analysis, patients with good performance status being treated in public hospitals were significantly more likely than patients treated at the tertiary cancer center to be in the highsymptom group (odds ratio, 5.6; 95% CI, 2.1 to 14.6; P = .001) and to report significantly higher symptom interference (P = .001). Other univariate predictors of high-symptom group membership included variables associated with being medically underserved (eg, having less education, being single, and being nonwhite). No group differences by ethnicity were observed in the public hospitals. Medically underserved patients were less likely to receive adequate pain management. Conclusion: Patients with advanced lung cancer and good performance status treated at public hospitals were more likely than those treated at a tertiary cancer center to experience substantial symptoms during chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=79960736597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960736597&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.33.4425

DO - 10.1200/JCO.2010.33.4425

M3 - Article

C2 - 21690477

AN - SCOPUS:79960736597

VL - 29

SP - 2859

EP - 2865

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 21

ER -